Clinical Trial Update: AAV1-CMV-Serca2a GENe Therapy Trial in Heart Failure [Phase 2]

View source ↗

Summary

A phase 2 trial evaluating AAV1-CMV-SERCA2a gene therapy for heart failure, including congestive heart failure and ischemic or non-ischemic cardiomyopathy, has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Ischemic Cardiomyopathy
• Non-ischemic Cardiomyopathy

Drugs mentioned

• AAV1-CMV-SERCA2a gene therapy

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Heart Failure Congestive, Ischemic Cardiomyopathy | Phase 2 | Status: TERMINATED